EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtVergleichsstudieÜbersichtsarbeit

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution

Matheus Souza iD, Lubna Al-Sharif iD, Vanio L J Antunes iD, Shi Yin Wong iD, Daniel Q Huang iD, Rohit Loomba iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70565 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Matheus Souza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Liver Cirrhosis, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Ministry of Health, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The burden of metabolic dysfunction‐associated steatohepatitis (MASH) cirrhosis is rapidly rising globally. There are several therapeutic agents under clinical development for the treatment of cirrhosis due to MASH; however, their relative efficacy has not been systematically assessed. This systematic review and network meta‐analysis was performed to compare the histological efficacy of available therapeutic agents for compensated MASH cirrhosis.

Methods

PubMed and Cochrane Library databases were searched from inception to May 25, 2025, for randomised controlled trials (RCTs) evaluating pharmacological treatments in patients with biopsy‐proven compensated MASH cirrhosis (F4c). The primary endpoint was fibrosis regression of at least one stage without MASH worsening, and the secondary endpoint was MASH resolution. Treatment comparisons were conducted via network meta‐analysis, and ranking probabilities were estimated using the surface under the cumulative ranking (SUCRA) curve analysis.

Results

Nine RCTs with 3266 participants met the eligibility criteria. Efruxifermin was the only intervention significantly superior to placebo for ≥ 1‐stage fibrosis improvement without worsening of MASH. The highest‐ranked interventions for fibrosis improvement were efruxifermin (SUCRA: 77.44), cilofexor + firsocostat (SUCRA: 72.38) and aldafermin (SUCRA: 71.27). For MASH resolution, efruxifermin, semaglutide + cilofexor + firsocostat and semaglutide were significantly superior to placebo. Efruxifermin (SUCRA: 81.38), semaglutide + cilofexor + firsocostat (SUCRA: 74.07) and semaglutide (SUCRA: 63.88) had the highest probability of ranking best for MASH resolution.

Conclusion

This network meta‐analysis provides relative rank‐order estimates of the histological efficacy of available pharmacological therapies for compensated MASH cirrhosis. These data may have implications for the design of future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisNon-alcoholic Fatty Liver DiseaseFatty LiverHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

MASHadvanced liver fibrosisnetwork meta‐analysisnonalcoholic steatohepatitispharmacological therapies

Autor:innen und Institutionen

  • Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Department of Biomedical Sciences and Basic Clinical Skills, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
  • Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
  • Yong Loo Lin School of Medicine, National University Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.
  • MASLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla, California, USA.

ORCID-Profile: Matheus Souza, Lubna Al-Sharif, Vanio L J Antunes, Shi Yin Wong, Daniel Q Huang, Rohit Loomba

Förderung

  • Ministry of Health
  • National Medical Research Council

Zitieren

APA

Souza, M., Al-Sharif, L., Antunes, V. L. J., Wong, S. Y., Huang, D. Q., & Loomba, R. (2026). Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70565

Vancouver

Souza M, Al-Sharif L, Antunes VLJ, Wong SY, Huang DQ, Loomba R. Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70565

BibTeX
@article{Souza2026,
  author = {Souza, Matheus and Al-Sharif, Lubna and Antunes, Vanio L J and Wong, Shi Yin and Huang, Daniel Q and Loomba, Rohit},
  title = {Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70565}
}
Kostenlos starten →